Impact of the Treatment Line on the Risks and Benefits of Immune Checkpoint Inhibitors in Patients With Non-Small Cell Lung Cancer and Interstitial Lung Disease
- Resource Type
- Correspondence
- Source
- In
Chest July 2022 162(1):e67-e69 - Subject
- Language
- ISSN
- 0012-3692